
In the News
Links to recent media coverage about Pervasis are found below.
2011
November 14, 2011
Boston Globe
"Biotech firms target tumors' neighborhoods"
September 15, 2011
Boston Business Journal
"MIT's Langer wins 'Golden Globe' of science "
September 7, 2011
Nature Medicine
"Taking tissue engineering to heart"
May/June 2011
MIT technology review
"Keeping Cancer in Check"
May 1, 2011
Pharmaceuticals Approvals Monthly
"Variety of Novel Approaches Marks Next-Gen Cancer Therapies at AACR"
April 7, 2011
BioWorld Today
"AACR Roundup"
March 1, 2011
Boston Globe
"Pervasis drug gets orphan status in Europe"
March 1, 2011
Mass High Tech
"Pervasis drug candidate gets EU orphan drug status"
February 8, 2011
Mass High Tech
"Pervasis hemodialysis treatment lands FDA fast-track review"
February 3, 2011
SciBX
"Implanting tumor control"
February 1, 2011
Drug Discovery & Development
"The Challenge of Cell Therapies"
February 1, 2011
Xconomy
"Pervasis in "Advanced" Talks with Potential Partners for Blood-Vessel Healing Product, CEO Says"
January 20, 2011
Mass High Tech
"Pervasis broadens to cancer therapeutics, eyes new financings"
January 20, 2011
BioWorld Today
"Other News To Note: Pervasis Therapeutics"
January 19, 2011
MedNous
"Pervasis Therapeutics explores endothelial cell-based approach to cancer"
January 19, 2011
MIT media relations
"MIT scientists discover cancer-fighting role for cells"
2010
November 10-17, 2010
Paris Match
"PAD: A Cell Therapy Against Recurrence" [english]
October 27, 2010
Mass High Tech
"MHT All-Star Frederic Chereau: Working to make lives better"
August 31, 2010
Mass High Tech
"MHT All-Stars"
August 26, 2010
Drug Discovery & Development
"A Novel Approach to Treating Peripheral Arterial Disease"
August 18, 2010
Mass High Tech
"Regenerative medicine gets on a profitable roll"
July / August 2010
Drug Delivery Technology
"The Power of the Endothelium: Novel Delivery Approaches to Promoting Vascular Healing"
April 23, 2010
Fierce Biotech
"Regenerative medicine could be $20B market in 15 years"
April 14, 2010
Mass High Tech
"BIOMEDevice Forum panelists talk of life sciences' cross sections"
March 26, 2010
New York Times
"Replacement Bones, Grown to Order in the Lab"
February 26, 2010
Mass High Tech
"BioForum panelists make case for partnership credibility"
February 2, 2010
The Boston Business Journal
"FDA clears track for Pervasis drug trial"
2009
September 16, 2009
The Boston Globe
“Pervasis completes initial closing of $17m round”
May 2009
Scientific American
“Progress in Tissue Engineering” [PDF]
2008
December 5, 2008
Mass High Tech
“The Mover: Frederic Chereau brings big-biotech experience to startup Pervasis Therapeutics” [PDF]
October 21, 2008
Xconomy
“Pervasis, Maker of Product to Heal Blood Vessels, Hires Genzyme Exec as First CEO” [PDF]
October 21, 2008
Mass High Tech
“Former Genzyme exec heads Pervasis Therapeutics"
October 21 , 2008
The Boston Globe
“Pervasis appoints chief executive”
October 21, 2008
Boston Business Journal
“Genzyme exec becomes new Pervasis CEO”
May 22, 2008
Science
“Engineering a Healing"
May 4, 2008
MIT news
“MIT researchers find novel way to repair airway injuries”
January 22, 2008
The Regeneration Station
“Pervasis Advances Tissue Engineered Products for Vascular Health”
January 15, 2008
The Boston Globe
“Pervasis secures additional funding”
January 15, 2008
Boston Business Journal
“Pervasis Therapeutics closes on $9.75M funding round”
January 15, 2008
Mass High Tech
“Pervasis to pump up blood vessel repair tech with $10M round”
January 15, 2008
Xconomy
“Pervasis Picks Up $9.75M”
2007
June 26, 2007
Technology Review
“Healing Blood Vessels”
March 20, 2007
Boston Business Journal
“Pervasis Starts Phase II Trials on Vascular Drug”
2006
November 2006
Cardiovascular Innovations
“Cellular ‘wrap’ may help regenerate damaged vessels”
October 20, 2006
Mass High Tech
“Cell Culture”
October 2, 2006
The Boston Globe
“Cells, Not Tools, May Help Fix Arteries” [PDF]
News + Events
Vascular Healing
We think about vascular healing in a fundamentally new way. >>
Clinical Programs
Learn more about our lead development candidates. >>





